Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy

Mark C. Markowski, Pedro Isaacsson Velho, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Emmanuel S. Antonarakis, Samuel R. Denmeade, Steven P. Rowe

Research output: Contribution to journalArticlepeer-review

Abstract

Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL-avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.

Original languageEnglish (US)
Pages (from-to)1270-1273
Number of pages4
JournalJournal of Nuclear Medicine
Volume62
Issue number9
DOIs
StatePublished - Sep 1 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Keywords

  • PSMA
  • early progression
  • testosterone

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy'. Together they form a unique fingerprint.

Cite this